Immunovant (IMVT)
(Delayed Data from NSDQ)
$27.87 USD
-1.00 (-3.46%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $27.88 +0.01 (0.04%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Immunovant, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 635 | 377 | 494 | 400 | 101 |
Receivables | 6 | 1 | 13 | 1 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 25 | 27 | 6 | 8 | 5 |
Total Current Assets | 666 | 404 | 513 | 409 | 109 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 666 | 406 | 516 | 412 | 109 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 1 | 19 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 41 | 40 | 25 | 15 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 3 |
Total Current Liabilities | 49 | 43 | 45 | 19 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 49 | 43 | 46 | 21 | 15 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,442 | 928 | 825 | 590 | 185 |
Retained Earnings | -826 | -566 | -355 | -199 | -91 |
Other Equity | 2 | 1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 618 | 362 | 470 | 391 | 94 |
Total Liabilities & Shareholder's Equity | 666 | 406 | 516 | 412 | 109 |
Total Common Equity | 618 | 362 | 470 | 391 | 94 |
Shares Outstanding | 145.20 | 130.20 | 116.40 | 97.90 | 64.80 |
Book Value Per Share | 4.25 | 2.78 | 4.04 | 4.00 | 1.45 |
Fiscal Year End for Immunovant, Inc falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 635 | 691 | 270 | 330 |
Receivables | NA | 6 | 1 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 25 | 19 | 20 | 19 |
Total Current Assets | NA | 666 | 711 | 291 | 350 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 666 | 711 | 292 | 351 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 4 | 8 | 26 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 41 | 28 | 32 | 24 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 49 | 32 | 40 | 51 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 49 | 32 | 40 | 51 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,442 | 1,430 | 950 | 940 |
Retained Earnings | NA | -826 | -750 | -699 | -640 |
Other Equity | NA | 2 | -1 | 1 | 1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 618 | 679 | 252 | 300 |
Total Liabilities & Shareholder's Equity | NA | 666 | 711 | 292 | 351 |
Total Common Equity | 0 | 618 | 679 | 252 | 300 |
Shares Outstanding | 146.10 | 145.20 | 144.60 | 130.60 | 130.50 |
Book Value Per Share | 0.00 | 4.25 | 4.70 | 1.93 | 2.30 |